Duff & Phelps Investment Management Co. Has $915,000 Position in Bristol-Myers Squibb Co (BMY)

Share on StockTwits

Duff & Phelps Investment Management Co. raised its stake in Bristol-Myers Squibb Co (NYSE:BMY) by 2.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 17,605 shares of the biopharmaceutical company’s stock after purchasing an additional 420 shares during the period. Duff & Phelps Investment Management Co.’s holdings in Bristol-Myers Squibb were worth $915,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Winslow Capital Management LLC purchased a new position in Bristol-Myers Squibb during the third quarter worth about $378,839,000. Jennison Associates LLC boosted its holdings in Bristol-Myers Squibb by 23.4% during the third quarter. Jennison Associates LLC now owns 21,526,559 shares of the biopharmaceutical company’s stock worth $1,336,369,000 after purchasing an additional 4,080,245 shares during the last quarter. Massachusetts Financial Services Co. MA boosted its holdings in Bristol-Myers Squibb by 44.3% during the third quarter. Massachusetts Financial Services Co. MA now owns 9,460,148 shares of the biopharmaceutical company’s stock worth $587,287,000 after purchasing an additional 2,903,920 shares during the last quarter. BlackRock Inc. boosted its holdings in Bristol-Myers Squibb by 2.4% during the third quarter. BlackRock Inc. now owns 114,573,885 shares of the biopharmaceutical company’s stock worth $7,112,747,000 after purchasing an additional 2,660,326 shares during the last quarter. Finally, FIL Ltd boosted its holdings in Bristol-Myers Squibb by 1,510.7% during the third quarter. FIL Ltd now owns 2,561,604 shares of the biopharmaceutical company’s stock worth $159,023,000 after purchasing an additional 2,402,567 shares during the last quarter. 72.56% of the stock is owned by hedge funds and other institutional investors.

Several research firms recently weighed in on BMY. Credit Suisse Group restated a “hold” rating and set a $59.00 price target on shares of Bristol-Myers Squibb in a report on Thursday, December 13th. BMO Capital Markets boosted their price target on shares of Bristol-Myers Squibb from $55.00 to $58.00 and gave the stock a “market perform” rating in a report on Friday, November 16th. ValuEngine upgraded shares of Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a report on Friday, December 7th. William Blair restated an “outperform” rating on shares of Bristol-Myers Squibb in a report on Tuesday, November 27th. Finally, Societe Generale set a $47.00 price target on shares of Bristol-Myers Squibb and gave the stock a “sell” rating in a report on Wednesday, November 14th. One research analyst has rated the stock with a sell rating, thirteen have given a hold rating and seven have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $60.03.

Shares of NYSE:BMY opened at $51.30 on Thursday. The firm has a market capitalization of $83.83 billion, a PE ratio of 12.89, a P/E/G ratio of 1.63 and a beta of 0.83. Bristol-Myers Squibb Co has a one year low of $44.30 and a one year high of $68.88. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.40 and a current ratio of 1.53.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, January 24th. The biopharmaceutical company reported $0.94 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.85 by $0.09. Bristol-Myers Squibb had a net margin of 21.95% and a return on equity of 50.03%. The company had revenue of $5.97 billion during the quarter, compared to analysts’ expectations of $5.95 billion. During the same quarter in the prior year, the company earned $0.68 EPS. The firm’s revenue was up 9.6% on a year-over-year basis. Research analysts expect that Bristol-Myers Squibb Co will post 4.16 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which was paid on Friday, February 1st. Stockholders of record on Friday, January 4th were paid a $0.41 dividend. This is a boost from Bristol-Myers Squibb’s previous quarterly dividend of $0.40. The ex-dividend date of this dividend was Thursday, January 3rd. This represents a $1.64 dividend on an annualized basis and a dividend yield of 3.20%. Bristol-Myers Squibb’s dividend payout ratio is 41.21%.

ILLEGAL ACTIVITY WARNING: “Duff & Phelps Investment Management Co. Has $915,000 Position in Bristol-Myers Squibb Co (BMY)” was originally reported by Macon Daily and is the sole property of of Macon Daily. If you are viewing this piece on another site, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://macondaily.com/2019/02/21/duff-phelps-investment-management-co-has-915000-position-in-bristol-myers-squibb-co-bmy.html.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic areas, such as oncology; cardiovascular; immunoscience; and human immunodeficiency virus (HIV) infection. Its products include Opdivo, a biological product for anti-cancer indications; Eliquis, an inhibitor targeted at stroke prevention in atrial fibrillation and prevention and treatment of venous thromboembolic disorders; Orencia, a biological product that targets adult patients with active rheumatoid arthritis and prostate-specific antigen; and Sprycel, a tyrosine kinase inhibitor for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

Further Reading: What are gap-down stocks?

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.